key: cord-1000353-zz93ijh6 authors: Marinaki, Smaragdi; Xagas, Efstathios; Tsoutsoura, Paraskevi; Katsaros, Dimitriοs; Korogiannou, Maria; Boletis, Ioannis N. title: Occurrence of severe SARS-COV-2 infection in fully vaccinated solid organ transplant recipients date: 2021-12-31 journal: Transplant Proc DOI: 10.1016/j.transproceed.2021.12.012 sha: 23fb824c5e5ad2179affd35997dcb0e93d17fbf7 doc_id: 1000353 cord_uid: zz93ijh6 The present study presents the clinical outcome of SARS-COV-2 disease in relation to the humoral response in fully vaccinated Solid Organ Transplant (SOT) recipients. Our patient cohort consists of 455 SOT recipients, vaccinated with one of the two approved mRNA vaccines. The antibody response was measured one month after the second dose and previously infected patients has been excluded. Of the 449 remaining patients, 15 (3.34%) tested positive, using SARS-COV-2 PCR. Mean age of them was 43.7 ±14.4 years and median time from transplantation was 7.8 years (1.2- 30.2). 11 patients (73.3%) had been vaccinated with BNT162b2 and 4 (26.7%) with the mRNA1273 vaccine. At the time of infection 9 (60%) patients had a negative (<50AU/ml) antibody titer, while 6 (40%) a positive one (>50AU/ml). Median antibody titer, 27.4± 14.0 days after the second dose, measured at 13AU/ml (0-7480AU/ml). Renal function did not appear to be affected by the disease. Τhe mean eGFR at diagnosis was 48 ± 15 ml/min, when in a 29(1-101) day median follow-up was 53.9± 20.9ml/min. Of the 15 patients, 7 had mild symptoms, and were not hospitalized, while of the remaining 8 (53.3%) who needed hospitalization, 7 had severe disease and 2 of them expired. The study confirms the variable and often severe course of COVID-19 infection in SOT recipients, even after their full vaccination, highlighting the need to vaccinate their close relatives and to accelerate the implementation of the booster dose of vaccine. Solid organ transplant (SOT) recipients represent a high-risk group for all SARS-COV-2 infection-related adverse outcomes with early case fatality rates (CFR) approaching 20% have been reported (1) . However, they have been excluded from all phase 3 vaccination trials. After their prioritization for COVID-19 vaccination in most countries, there is increasing evidence about alarmingly low response rates to both mRNA vaccines. In a recently published systematic review, the pooled estimate of antibody response after full vaccination in SOT recipients was at 35% (2) . Notably, regarding humoral response to the SARS-COV-2 vaccines, even compared to other immunocompromised patient groups, SOT recipients perform worse. In a recent study by Haidari et al, among different immunosuppressive conditions, seropositivity was the lowest in SOT recipients; 37.2% compared to 54.7% and 82.4% in patients with hematologic malignancies and solid tumors respectively(3). Most disturbingly, besides reduced immunogenicity to vaccinations, as already known by other vaccines, lifelong immunosuppression is associated with suboptimal immune response to viral pathogens (4) . First reports about occurrence of COVID-19 infection with variable and often severe disease course in SOT recipients after full vaccination have been published (5) implicating the urgent need for more data. The present study assessed the disease course and the clinical outcomes of SARS-COV-2 infection in relation to humoral response after full vaccination with one of the two mRNA SARS-COV-2 vaccines in 15 out of a large cohort of 449 SOT recipients. Since all SOT recipients are actively followed and hospitalized if necessary, in the transplant unit of either of the two reference hospitals of Athens, it is highly unlikely that a transplanted patient with a serious problem such as a positive PCR-test for SARS-COV-2 could be missed. Furthermore, most of them underwent PCR-testing for various reasons, as in Greece, it is mandatory for several activities, even after full vaccination. Even those who were asymptomatic followed the advice to contact their transplant physicians, which are all working in the two abovementioned hospitals. After a positive PCR they were treated as outpatients with laboratory and clinical evaluation once to twice a week. The study was approved by the Ethics committee of the Onassis Cardiac Surgery Center. According to the FDA, mild disease was characterized by fever, cough, malaise, myalgias, anosmia and ageusia and other less common symptoms i.e from gastrointestinal tract as nausea, vomiting or diarrhea in the absence of low respiratory tract involvement. Moderate disease included lower respiratory tract involvement with infiltrates on chest imaging without dyspnea or hypoxia. Severe disease was defined as presence of lung infiltrates with hypoxia: oxygen saturation at room air less than 94% and/or need for oxygen supplementation or ventilator support. Breakthrough infection, defined as positive SARS-COV-2 PCR more than 14 days after completion of the 2 nd vaccination dose, occurred in 15 out of 449 (3.34%) recipients, 13 kidney, one heart and one kidney-heart recipient respectively. Twelve out of 15 patients As depicted in table 1, at least one comorbidity was present in all SOT recipients. All were transplanted for more than one year and received stable maintenance immunosuppression. In the 13 kidney transplant recipients, modification of immunosuppression at the time of COVID-19 infection consisted of withdrawal of the antimetabolite and reduction of Tacrolimus with target levels below 6ng/ml, while in the one heart and the two kidney-heart recipients, Tacrolimus was reduced without withdrawal of the antimetabolite. In those who recovered, immunosuppression was gradually restored to pre-infection levels after three weeks. Treatment for COVID-19 comprised of prophylactic dose of low-molecular weight heparin (LMWH) for one month to all, regardless of disease severity. Broad spectrum antibiotics were administered to 5 patients with elevated markers of inflammation and dexamethasone and the antiviral Remdesivir to the 7 patients with severe disease. Disease severity was categorized according to the FDA definitions. Disease course was variable: out of the 15 infected patients, 7 had minimal symptoms or mild disease and were not hospitalized. Eight of the 15 recipients (53.3%) were hospitalized: one had moderate and 7 had severe disease. From those, 2 developed life-threatening disease; the first developed severe respiratory insufficiency, was intubated and expired in the ICU from sepsis, while the second patient was one heart recipient who died after a long and complicated hospitalization from gram negative sepsis. Median time of hospitalization was 9 days (6-57). As feared by many transplant physicians, breakthrough infection is a major issue in SOT recipients and correlates with low or undetectable antibody titers. Most disturbingly, from the few data available, in transplanted patients, COVID-19 infection after full vaccination, does not seem to run a more indolent course (2) . The biggest cohort published until today by Caillard et al (8) included 55 patients after kidney and kidney-pancreas transplantation. Similar to ours, they also found a variable clinical course. Hospitalization rate in their cohort was lower at 27% compared to 53% in our study. From the 15 hospitalized patients in the French cohort, 6 were admitted to the intensive care unit (ICU) and 3 out of 15 (20%) died. We found a case fatality rate (CFR) of 25% (2 out of 8) among our hospitalized SOT recipients. Of course, numbers are too small to draw definite conclusion, but they are indicative of an unpredictable and often fatal disease course. Regarding immunogenicity, in the French study, only one patient among the 25 in whom antibody titers were available, had positive titers. In our study, antibody positivity was present in 40% of SOT recipients (6 out of 15) but with low titers. The weak immune response and the unpredictable disease course of breakthrough infection has already prompted some National Health Authorities as the French to recommend a third vaccination dose in SOT recipients with the first studies reporting safety and improved immunogenicity after administration of the booster dose (9,10) . The present study indicates a variable and often severe disease course of COVID-19 infection in transplanted patients, even after full vaccination. We found a rate of breakthrough infection of 3.34% with numbers of infected SOT recipients growing every day. Unfortunately, we also recorded a variable, often severe and even fatal disease course among infected individuals. These findings, besides continuous practice of safety measures and "cocooning" vaccination of their close relatives, strongly implicate reevaluation of the vaccination policy with rapid implementation of the booster dose, as is already approved in many countries including ours. This work was supported by the Onassis Cardiac Surgery Center (fund 704/13.01.2021). None of the authors was compensated for his or her contributions and the funder had no role in the design and conduct of the study. ANTI BODI ES POSI TIVIT Y ANTIBOD IES TITER YEARS FROM Tx TO FIRST POSITIVE PCR TEST DAYS FROM 2ND DOSE TO FIRST POSITIVE PCR TEST SEVERITY OF COVID-19 TREATMENT FOR COVID-19 A Systematic Review of COVID-19 Infection in Kidney Transplant Recipients: A Universal Effort to Preserve Patients' Lives and Allografts Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis Serologic vaccination response after solid organ transplantation: a systematic review Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months Occurrence of severe COVID-19 in vaccinated transplant patients Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses